证券代码：300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 编号：2023-004 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（2023 年半年度业绩交流会） | | 华安证券 参与单位名称 | 谭国超 李雨涵 刘洪飞 | | 民生医药 | 王班 宋丽莹 易美娟 | | 及人员姓名 瓦琉咨询 | 杨云添 梁羽蒙 符传宏 滕美忻 | | 健顺投资 | 张琦悦 | | 时间 2023 | 年 8 月 29 日 下午 15：00-16：00 | | 地点 线上会议 | | | 上市公司接待 | 董事、副总裁、董事会秘书 林 强 | | 人员姓名 财务总监 | 王庆国 纪要内容： | | 况。 | 一、由公司董事、副总裁、董事会秘书林强致欢迎辞，介绍公司基本情 | | 投资者关系活 每股收益 | 2023 年上半年，公司实现营业收入 6.34 亿元，同比增长 32.18%；基本 0.39 元/股，同比上升 89.44%。 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥633.73 million, representing a 32.18% increase compared to ¥479.43 million in the same period last year[28]. - Net profit attributable to shareholders was ¥155.73 million, up 89.45% from ¥82.20 million year-on-year[28]. - The net profit after deducting non-recurring gains and losses was ¥149.63 million, an increase of 137.42% compared to ¥63.02 million in the previous year[28]. - Basic earnings per share rose to ¥0.3876, reflecting an increase of 89.44% from ¥0.2046 in the same period last year[28]. - The company's total assets at the end of the reporting period were ¥3.09 billion, a 1.04% increase from ¥3.06 billion at the end of the previous year[28]. - Net assets attributable to shareholders increased by 6.85% to ¥2.43 billion from ¥2.27 billion at the end of the previous year[28]. - The net cash flow from operating activities decreased by 10.59% to ¥101.26 million from ¥113.26 million in the previous year[28]. - The weighted average return on equity improved to 6.62%, up from 3.89% in the same period last year[28]. - The company's revenue for the reporting period reached ¥633,725,687.05, representing a year-on-year increase of 32.18% due to a rebound in market demand[48]. - The gross profit margin for the pharmaceutical manufacturing sector was 67.33%, an increase of 4.65% compared to the previous year, with revenue from this sector amounting to ¥577,820,675.91[50]. Product Portfolio and Market Position - The company reported a significant reliance on its main products, particularly the "Kuaike" cold medicine series, which accounted for a high percentage of both revenue and gross profit during the reporting period[5]. - The company has over 90 drug production approval numbers and 6 health food production approval numbers, indicating a diverse product portfolio[6]. - The "Kuaike" brand has maintained a leading position in the cold medicine market, ranking first in the annual comprehensive statistics for non-prescription drugs in the "cold category" for three consecutive years from 2020 to 2022[36]. - The company has developed a product line covering various therapeutic areas, including respiratory, digestive, orthopedic, and pediatric medicine, with a focus on cold and flu relief, gastrointestinal health, and nutritional supplements[37]. - The "Kuaike" and "Xiaokuaike" brands have become household names in China, with significant brand recognition and competitive advantages, having received the "well-known trademark" honor[37]. - The company is expanding its market share in health products by utilizing online sales channels and has established a B2C e-commerce platform on major platforms like Tmall and JD[38]. - The company is actively promoting prescription drug development and expanding its product line through academic promotion and agent expansion[39]. - The company has successfully developed and launched the traditional Chinese medicine "Xuduan Zhuanggu Capsule," which is classified as a Category II new drug and targets primary osteoporosis, indicating a broad market potential[40]. Research and Development - The company plans to enhance its R&D efforts with over ten ongoing projects, focusing on adult upper respiratory and calcium supplement series products[6]. - Research and development investment increased by 27.27% to ¥27,863,062.95, driven by higher clinical trial and external research costs[48]. - The company is actively developing high-end raw materials such as calcium carbonate and expanding its market presence both domestically and internationally, focusing on customized, high-quality products[40]. - The company is committed to expanding its capabilities in the new materials and machinery sector, focusing on innovative solutions for market demands[42]. - The company is enhancing its product technology through customer feedback, driving iterative upgrades in its offerings[41]. Financial Strategy and Investments - The company does not plan to distribute cash dividends or issue bonus shares for the reporting period[8]. - The company has not made any changes to its registered address or contact information during the reporting period[25]. - The company has ongoing major non-equity investments, including the Zhejiang Yafeng Pharmaceutical production base project, with a total investment of ¥23,106,000[59]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period, reflecting a conservative financial strategy[64]. - The company has reported a significant increase of 102.55% in net cash flow from investment activities, amounting to ¥1,071,131.45, influenced by financial investments[48]. Environmental Compliance - The company strictly adheres to environmental protection laws and standards, with subsidiaries included in the key pollutant discharge unit list[80]. - The company has implemented continuous monitoring of wastewater discharge, ensuring compliance with the GB040600 standards[88]. - The company achieved compliance with the GB16297-1996 air pollution discharge standards, with no exceedances reported[87]. - The company has established a stable discharge flow, ensuring that emissions remain within permissible limits[88]. - The company is committed to maintaining environmental standards and has not reported any exceedances in pollutant discharge[87]. Corporate Governance and Shareholder Relations - The company has not experienced any environmental pollution incidents or disputes during the reporting period, adhering to national and local environmental protection laws[104]. - The company actively engages in investor relations activities to ensure long-term harmonious development with shareholders[102]. - The annual shareholders meeting had a participation rate of 57.89% on May 26, 2023[74]. - The company has not conducted any repurchase transactions during the reporting period[138]. - The total number of shareholders at the end of the reporting period is 23,687[137].

公司负责人（法定代表人） ： 魏宝康 主管会计工作负责人 ： 王庆国 会计机构负责人 ： 王庆国 四川金石亚洲医药股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司 | 上市公司核 | 2023年期初占用资 | 2023年半年度占用 | 2023年半年度占用资金 | 2023年半年度偿还 | 2023年期末占用资 | | | | 非经营性资金占用 | 资金占用方名称 | 的关联关系 | 算的会计科 | 金余额 | 累计发生金额（不 | 的利息（如有） | 累计发生金额 | 金余额 | 占用形成原因 | 占用性质 | | | | | 目 | | 含利息） | | | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东 、实际控制人及其附属 ...

四川金石亚洲医药股份有限公司 独立董事关于第四届董事会第九次会议相关事项的独立意见 1、报告期内，未发现控股股东及其他关联方非经营性占用公司资金情况。 根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳证券交易所 创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》和四川金石亚洲医药股份有限公司（以下简称"公司"）《公 司章程》、《独立董事工作制度》的有关规定，我们作为公司独立董事，对公司 2023 年上半年度资金占用及对外担保情况及公司第四届董事会第九次会议审议 的《关于与参股公司签订技术开发合同暨关联交易的议案》进行了认真审查，在 仔细审阅公司提供的相关资料，并听取有关人员说明的基础上，基于独立、客观 判断的原则，现发表意见如下： 一、对公司 2023 年上半年度资金占用及对外担保情况的独立意见 2、报告期内，未发现新增对外担保，也不存在以前期间发生并延续到报告 期的对外担保。截止 2023 年 6 月 30 日，公司对外担保余额为人民币 0 元。 综上，我们认为公司严格执行了《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》（证监 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-026 四川金石亚洲医药股份有限公司 关于与参股公司签订技术开发合同暨关联交易的公告 本公司及董事会全体成员、保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 基于四川金石亚洲医药股份有限公司（以下简称"公司"）业务发展需要，为 进一步丰富产品管线，助力公司建立产品差异化竞争优势，打造新的技术壁垒和利 润增长点，公司全资公司浙江亚克药业有限公司（以下简称"亚克药业"）与公司 参股公司杭州领业医药科技有限公司（以下简称"领业医药"）分别签订《技术开 发合同》，委托领业医药进行骨化三醇软胶囊、布洛芬软胶囊、ω-3 脂肪酸乙酯 90 软胶囊项目的技术开发工作，交易金额合计人民币 1,412 万元（含税）。 领业医药为公司之参股公司，公司持有其 28.96%的股份。鉴于公司董事长、 总经理魏宝康先生现担任领业医药董事长，公司董事盛晓霞女士现担任领业医药 董事兼总经理。此外，公司第一大股东高雅萍女士直接持有领业医药 25.66%的股 份。根据《深圳证券交易所创业板股票上市规则》有关规定，领业医药为公司关联 法人。 ...

根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳证券交易所 创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》和四川金石亚洲医药股份有限公司（以下简称"公司"）《公 司章程》、《独立董事工作制度》的有关规定，我们作为公司独立董事，对拟提交 公司第四届董事会第九次会议审议的《关于与参股公司签订技术开发合同暨关联 交易的议案》进行了事先审查。基于独立、客观判断的原则，现发表事前认可意 见如下： 四川金石亚洲医药股份有限公司 独立董事关于第四届董事会第九次会议相关事项 的事前认可意见 本次关联交易定价公允，符合公司业务发展需要，有利于进一步丰富公司产 品管线，不存在损害公司及全体股东、特别是中小股东利益的情形。我们一致同 意将《关于与参股公司签订技术开发合同暨关联交易的议案》提交公司第四届董 事会第九次会议审议。董事会审议本次关联交易事项时，关联董事魏宝康先生、 盛晓霞女士应当回避表决。 （以下无正文） 二〇二三年八月二十七日 独立董事： ______________ ______________ ______________ ______________ 马 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-022 四川金石亚洲医药股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届董事会第九次 会议于 2023 年 8 月 27 日上午 9：30 以通讯表决方式召开。本次董事会会议通知 已于 2023 年 8 月 24 日以电子邮件或网络方式发出。会议应出席董事 11 名，实 际出席董事 11 名。本次会议由董事长魏宝康先生主持。本次会议的召集、召开 程序符合《公司法》及《公司章程》的有关规定，会议表决合法有效。 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2023 年半年度报告全文及摘要》 《2023 年半年度报告》详见公司同日在巨潮资讯网发布的相关公告，《2023 年半年度报告摘要》详见公司同日在巨潮资讯网及公司指定信息披露媒体发布的 相关公告。 公司监事会对公司《2023 年半年度报告全文及摘要》进行审核并发表了审 核意见；公司独立董事对控股股东及其 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-023 四川金石亚洲医药股份有限公司 第四届监事会第九次会议决议公告 二、监事会会议审议情况 经研究讨论，会议达成如下决议： 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届监事会第九次 会议于 2023 年 8 月 27 日上午以通讯表决方式召开，会议通知已于 2023 年 8 月 24 日以电子邮件或网络方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席汪进先生主持。本次会议的召集、召开符合《公司法》 及《公司章程》的有关规定，会议表决合法有效。 经审核，监事会认为：公司董事会编制和审核公司《2023 年半年度报告全 文及摘要》的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者 重大遗漏。 《2023 年半年度报告》详见公司同日在巨潮资讯网发布的相关公告，《2023 年半年度报告摘要》详见公司同日在巨潮资讯 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,242,603,080.88, representing a 17.95% increase compared to ¥1,053,504,604.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥218,786,883.71, a significant increase of 229.10% from ¥66,480,785.93 in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,753,270.89, up 244.90% from ¥56,756,082.55 in 2021[27]. - The net cash flow from operating activities for 2022 was ¥323,041,794.10, an increase of 136.84% compared to ¥136,395,575.72 in 2021[27]. - The total assets at the end of 2022 were ¥3,059,913,477.69, a 10.54% increase from ¥2,768,127,717.25 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥2,274,229,801.83, reflecting a 9.14% increase from ¥2,083,751,254.61 at the end of 2021[27]. - The basic earnings per share for 2022 was ¥0.54, a 217.65% increase from ¥0.17 in 2021[27]. - The weighted average return on equity for 2022 was 10.06%, up from 3.24% in 2021, indicating improved profitability[27]. - The company reported a net profit of ¥66,575,529.07 in Q1 2022, with a total operating revenue of ¥314,985,330.83 for the same quarter[29]. - The company reported a total non-operating income of 23,033,612.82, a significant increase of 136.5% compared to 9,724,703.38 in 2021[33]. Product Portfolio and Market Position - The company reported a significant reliance on its main product, the Kuaike cold medicine series, which accounted for a high percentage of both revenue and gross profit during the reporting period[5]. - The company has established over 90 drug production approval numbers and 6 health food production approval numbers, indicating a strong product portfolio[5]. - The company's main products include OTC medications such as "Kuaike" and "Xiaokuaike," which have maintained a leading market position in the cold medicine sector for three consecutive years[42]. - The company is focusing on the development of integrated raw material drug formulations and calcium mineral series products as future growth areas[6]. - The company is actively involved in the research and development of new drugs, focusing on respiratory, digestive, orthopedic, and pediatric areas[43]. - The company has developed multiple patented technologies in the field of ginsenoside RH2 extraction and produces high-quality health foods under the JinXing brand[44]. - The "Kuaike" and "Kuaike Junior" OTC drug series have become well-known cold medicine brands in China, with significant brand recognition and competitive advantages[44]. - The company is expanding its health food product range and has established a B2C e-commerce platform, reducing channel costs and inventory pressure compared to traditional manufacturers[44]. - The company is actively developing the "Kuaike Bencao" series of traditional Chinese medicine pieces, leveraging its brand influence and geographical advantages[45]. Competition and Market Risks - The company faces risks from increasing competition in the cold medicine and health food markets, which may threaten its market share due to new entrants and expanded capacities from existing companies[4]. - The company acknowledges the potential impact of regulatory changes in the pharmaceutical sector, which could alter the competitive landscape and operational models[6]. - The company anticipates ongoing price reductions in the pharmaceutical industry due to government policies, which may negatively impact average profit margins[7]. Research and Development - The company is investing in projects such as the Jinxi raw material drug project and the subsidiary formulation workshop renovation project, which involve substantial capital expenditures[6]. - The company has initiated a high-investment strategy in R&D, establishing a collaborative platform for innovation in the pharmaceutical sector[54]. - The company aims to enrich its product pipeline with various health supplements and generic drugs, focusing on expanding sales channels[69]. - The company is advancing multiple generic drug projects, including the consistency evaluation of Domperidone tablets, which is expected to enhance product competitiveness[69]. - Research and development (R&D) expenditure for 2022 amounted to CNY 39,184,819.23, accounting for 3.15% of operating revenue, down from 3.55% in 2021[71]. Supply Chain and Production - The company has a stable supply chain with long-term partnerships with key suppliers, although it remains vulnerable to potential raw material shortages and price increases due to external factors[5]. - The company operates five production bases across China, with a total area of over 400 acres, ensuring stable and efficient production capacity for various pharmaceutical forms[52]. - The company is investing in high-end raw materials, particularly calcium carbonate, to strengthen its market position in the calcium supplement category[47]. - The company has completed the development of a vacuum glass continuous production line, which is expected to significantly enhance production capacity and efficiency[72]. Marketing and Sales Strategy - The marketing network includes 1,200 chain agreements and over 92,000 cooperative chain stores, covering more than 90% of cities and 70% of counties in China[54]. - The company has built a large marketing team of over 1,000 members, enhancing its sales capabilities across both offline and online channels[55]. - The company is expanding its market presence through online TOB, TOC, and OTO platforms, aiming to enhance sales channels[93]. - The company plans to promote the upgrade of existing products, targeting the market with the KuaiKe cold medicine series and children's precision medication products over the next 2-3 years[92]. Environmental Responsibility - The company has established a comprehensive environmental management system to monitor and report on emissions and discharges[172]. - The company has implemented various pollution discharge standards across its subsidiaries to comply with environmental regulations[159][160][161]. - The company has established wastewater treatment facilities with a design capacity of 50 tons/day at the Asian Pharmaceutical Yagu plant and 15 tons/day at the Jinpan plant, achieving a stable operation rate of over 98%[175]. - The company has signed disposal contracts with qualified units for hazardous solid waste management, ensuring compliance with regulations[178]. - The company is committed to adhering to national environmental standards and has taken measures to monitor and control emissions effectively[169]. Governance and Compliance - The company has established a governance structure that complies with regulatory requirements and enhances decision-making processes[101]. - The board of directors consists of 11 members, including 4 independent directors, ensuring compliance with legal and regulatory standards[103]. - The company maintains strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[106]. - The company has established a clear internal control system with defined roles and responsibilities to ensure effective decision-making and management[150]. - The company has implemented an internal control audit for subsidiaries, enhancing risk management and control understanding[150]. Strategic Initiatives - The company plans to continue expanding its product lines and enhance its market presence through strategic initiatives and potential acquisitions[27]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its market share in the pharmaceutical industry[115]. - The company plans to utilize capital to strengthen its product pipeline and acquire strategically valuable targets[95]. - The company is focusing on improving management efficiency and addressing operational bottlenecks encountered in 2023[92].

证券代码：300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 编号：2023-003 □特定对象调研 □ 分析师会议 投资者关系活动 □ 媒体采访 √ 业绩说明会 类别 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 投资者网上提问 时间 2023 年 5 月 19 日 (周五) 下午 15:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络 远程的方式召开业绩说明会 1、董事长、总经理魏宝康 上市公司接待人 2、董事、副总经理、董事会秘书林强 员姓名 3、财务总监王庆国 4、独立董事汪立荔 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问董事长先生，贵公司管理层是否有信心使公司业绩在未来 年度保持持续增长，将采取何种措施确保公司保持持续健康发展？公 投资者关系活动 司目前及未来在经营过程中所面临的最大风险是什么？ 主要内容介绍 尊敬的投资者，您好！未来公司将通过以下安排继续推动公司发展： 1、提升优化丰富现有产品，利 ...